Greater OS Benefit Among Patients with Advanced Cancer Treated with Matched Targeted Therapy Based on Biomarkers Identified by ctDNA Genotyping By Ogkologos - November 11, 2024 856 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SCRUM-Japan GOZILA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Sacituzumab Govitecan Demonstrates Overall Survival Benefit Over Chemotherapy in Patients with... September 18, 2023 FDA Grants Accelerated Approval to Sonrotoclax for Relapsed or Refractory Mantle... May 27, 2026 FDA Approves Engineered Cell Therapy for Advanced Synovial Sarcoma August 27, 2024 Screening for Many Cancers with One Test: Uncertainty Abounds April 21, 2022 Load more HOT NEWS Molecular Analysis for Precision Oncology Congress 2023, 4–6 October 2023 Paris,... Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell... Dr Ian Walker on Smoking: ‘The killer behind the counter’ Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated...
